(redirected from Cravit)
Also found in: Medical.


A synthetic broad-spectrum antibiotic, C18H20FN3O4, of the fluoroquinolone class.



n levofloxacino, levofloxacina
References in periodicals archive ?
Daiichi Sankyo Company, Limited today announced that it has obtained approval for partial changes concerning a supplementary indication of their new quinolone antibacterial injections, Cravit Intravenous Drip Infusion Bag 500mg/100mL and CravitA Intravenous Drip Infusion 500mg/20mL (generic name: Levofloxacin Hydrate) to treat bacterial infections of urology, surgery, and gynecology.
Our study forecasts sales of 27 marketed drugs, including these brands: - Lucentis - Eylea - Restasis - Vigamox - Pataday/ Patanol - Jetrea - Lumigan and Ganfort - Xalatan/Xalacom - Zioptan - Cravit Discover how high revenues can go.
Zedd was founded by Craig Meilleur, Michael Cravit, Mike Rossman and Craig Minor, who have spent two decades operating call centres.
Sankyo and Daiichi Pharmaceutical have a broad range of major drug products on the Japanese market, including the antihypertensive Benicar (olmesartan medoxomil) and the synthetic antibacterial agent Cravit (levofloxacin).
Currently, levofloxacin is marketed under the trade names of Cravit in Japan and Levaquin in the US.
The company said sales of its main products slipped in the fiscal first half, with sales in Japan of its Cravit antibacterial agent falling by 1.
Before joining Douwe Egberts, Wonder was the account director at David Cravit & Associates Advertising.
Partnering with them now is really a matter of giving Zedd a bit of a head start and competitive advantage," said Michael Cravit, Executive Vice President of Zedd Customer Solutions.
Meanwhile, regarding Cravit, Daiichi Sankyo will continue to provide information on efficacy and safety to medical practitioners based on accumulated usage results up to now.
You find sales prospects for brands such as Hyalein, Tapros/Taflotan, Cravit, and Diquas, along with R&D, strategies and driving and restraining forces from 2014 onwards.
94 billion yen on robust growth in sales of Cravit, the mainstay synthetic antibacterial agent.
hereafter Daiichi Sankyo Espha), have submitted a supplemental New Drug Application (sNDA) in Japan for the synthetic broad-spectrum oral antibacterial agent Cravit Tablets 250mg and 500mg, Granules 10% (generic name: Levofloxacin hemihydrate) and Levofloxacin Tablets 250mg DSEP and 500mg DSEP, Granules 10% DSEP for the treatment of pulmonary and other tuberculosis disorders.